Opendata, web and dolomites

MetaTox-HS

Advanced Solutions for High Sensitivity Metabolism and Toxicity Assays

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MetaTox-HS project word cloud

Explore the words cloud of the MetaTox-HS project. It provides you a very rough idea of what is the project "MetaTox-HS" about.

   biosciences    standard    vivo    turnover    jobs    toxicity    revenue    challenger    3bn    made    vitro    demonstrated    serious    sub    contract    bedside    business    instrumentation    drug    highlights    few    oct    dominated    creation    ambition    global    re    previously    metabolism    readiness    industry    instruments    disease    expensive    opportunity    beneficiary    proof    capex    components    mitoxpress    position    polymer    full    tests    stages    sole    commercial    lux    academia    innovation    scientific    reader    passing    boost    translate    clear    synergy    plate    labs    5m    secures    metatox    solution    innovative    platform    requirement    13    enormous    pilot    party    submitted    microfabrication    businesses    electronic    cell    critical    consumable    cum    plan    16    kits    consolidating    criteria    market    320m    completes    scoring    reg    fluorescence    3rd    hs    trade    manufacturing    bench    luxcel    write    nanosensor    ltd    final    laboratory    flexible    models    2023    accessible    prototyped    doxycheck    job    pharmaceutical    review    scientists    engineering    est    verification    performance    either    uhs    14   

Project "MetaTox-HS" data sheet

The following table provides information about the project.

Coordinator
LUXCEL BIOSCIENCES LTD 

Organization address
address: BIOTRANSFER UNIT SUITE 3-32 BIOL
city: Cork
postcode: T12
website: www.luxcel.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.agilent.com/en/metatox-hs
 Total cost 1˙469˙333 €
 EC max contribution 1˙028˙533 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUXCEL BIOSCIENCES LTD IE (Cork) coordinator 1˙028˙533.00

Map

 Project objective

'Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for scientific tests and models of disease, for researchers in academia, institutions and the pharmaceutical industry, that better translate from the bench (in vitro) to the bedside (in vivo). Critical tests are either not available, or only available on a few large, expensive dedicated instruments.

Luxcel Biosciences Ltd (LUX) has prototyped innovation that can now bring these high performance tests, to all laboratory scientists, for use on standard laboratory instrumentation already available in est. 20,000 labs (fluorescence plate reader), without requirement for CapEx.

LUX’s business innovation solution is a platform of low cost, flexible, easy to use and accessible in vitro cell metabolism and toxicity test kits and consumable products (MitoXpress UHS® and dOxycheck™) made possible through innovative synergy of LUX’s fluorescence nanosensor technology, together with advanced polymer microfabrication and electronic engineering.

MetaTox-HS project, completes the final stages of development, verification, pilot process and manufacturing readiness, together with dissemination and exploitation activities, to bring the full product solution to market and secures EU based revenue and job creation; 13 new jobs and €14.5m cum turnover by 2023, consolidating LUXCEL’s EU position (2 YR), and ambition to become a serious #2 challenger in this est. €320m accessible US and global market (5 YR), currently dominated by US businesses.

Proposal previously submitted Oct ’16, scoring highly, passing all three criteria. Following a full commercial review LUXCEL has taken a sole beneficiary role, with key enabling technology provided through 3rd party sub-contract. A full re-write highlights: clear product components, demonstrated proof-of-concept, well-defined market opportunity and strong commercial plan to boost growth. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METATOX-HS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METATOX-HS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

NAS (2018)

Nexilis augmentation system

Read More  

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More